Purpose: to evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (cnV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (oct).
T he advent of intravitreal anti-vascular endothelial growth factor (VEgF) therapy has dramatically improved the visual outcomes in patients with neovascular age-related macular degeneration (aMd).
1 the safety and efficacy of monthly injections of 0.5 mg ranibizumab was established by the landmark randomized controlled studies (Marina and ancHor) 2, 3 where the majority of patients receiving ranibizumab (95% and 96%, respectively) maintained their vision (≤15 letters lost) and 34% and 40%, respectively, experienced at least a 15-letter gain in best corrected visual acuity (BcVa) from baseline accompanied by a rapid and sustained reduction in retinal thickness. as monthly injections of ranibizumab may impose a significant financial and physical burden on patients, placing them at higher risk of injection-related adverse effects, several reduced-dose regimens have been employed.
4-7 although good visual outcomes can be achieved with reduced-dose ranibizumab regimens, average gains in BcVa from baseline are consistently lower than those achieved with monthly dosing of ranibizumab. 8 aflibercept (Eylea, Bayer Healthcare ag, leverkusen) is a VEgF-receptor decoy that binds 3 members of the VEgF family of proteins: VEgF-a, VEgF-B, and placental growth factor (PlgF).
9,10 Because aflibercept has higher binding affinity for VEgF, a higher rate of association with VEgF, and a higher molecular weight than ranibizumab, it was predicted to be pharmacologically active for a longer period than ranibizumab.
11 the ViEW studies demonstrated that bimonthly dosing of 2 mg aflibercept (after 3 initial monthly doses) was clinically equivalent to monthly 0.5 mg ranibizumab at 12 months in patients with neovascular aMd with a similar safety profile.
12 the ViEW studies recruited treatment-naive patients. to prospectively evaluate the change in clinical response and course when patients with neovascular aMd previously treated with monthly ranibizumab injections and with persistent fluid on optical coherence tomography (oct) were switched to intravitreal aflibercept, we initiated the VEgF treatment of aMd switch study (the vtas study). materials and methods study design this study is an investigator-initiated, prospective, open-label study of 18 patients with persistent but stable fluid secondary to neovascular aMd previously treated with monthly injections of ranibizumab 0.5 mg who commenced intravitreal aflibercept treatment between december 1, 2012, and July 1, 2013. Participants were followed for approximately 1 year after their first aflibercept injection. Visual acuity and anatomical outcomes associated with aflibercept treatment were reviewed after 24 and 48 weeks.
institutional ethics approval was obtained from Bellberry Human research Ethics committee before study commencement, protocol reference number 2012-10-1093-aEr-1. the study adhered to the tenets of the declaration of Helsinki. informed consent was obtained from all participants before enrolment in the study. examination. the inclusion criteria included the following: age 50 years or older; cnV secondary to aMd as demonstrated by fluorescein angiography; BcVa between 6/6 and 6/60 using snellen charts routinely used within the practice [converted to approximate Early treatment diabetic retinopathy study (Etdrs) letter scores before analysis]; 13 persistent cnV defined as evidence of subretinal fluid (srF) or cystoid edema on spectral domain oct scan (sd-oct) less than 30 days since last treatment. stable disease was defined as follows: no reduction in visual acuity of 5 or more letters, no new intraretinal or clinically significant additional srF on oct, no new hemorrhage or new cnV, and at least 2 previous intravitreal ranibizumab injections before recruitment.
Exclusion criteria included the following: prior anti-VEgF injection in the study eye within 30 days of baseline; prior treatment with photodynamic therapy (Pdt) within 90 days of baseline and more than 6 prior Pdt treatments; significant subretinal fibrosis or atrophy; prior treatment with triamcinolone in the study eye within 6 months of baseline; prior vitrectomy or other surgical intervention.
treatment and assessments
Participants received 3 injections of 2 mg (0.05 ml) intravitreal aflibercept, monthly, for the first 8 weeks (loading phase). the interval between aflibercept injections was then extended up to 8 weeks, but further retreatment was performed according to the response to treatment (pro re nata; Prn) as determined by the treating retinal specialist. loss of vision of more than 5 letters or the presence of residual intra-or subretinal fluid was a trigger for retreatment.
aflibercept was supplied by Bayer australia ltd and was administered in accordance with the product information. at each visit the patient had a thorough eye examination including visual acuity and condition of the retina was assessed with sdoct. the patients' central macular subfield thickness (cMt) and central macular volume within 6 mm of the fovea (cMtVol) were measured using automated software, and software-specific calipers were used to manually measure the height of subretinal fluid and any pigment epithelial detachment (PEd). study endpoints the primary study endpoint was the number of participants who had less than 5 letters of vision loss at weeks 24 and 48 of the study. secondary outcomes at weeks 24 and 48 included the following: the mean change in vision from baseline; the proportion of patients with more than 5 letters of vision loss; the mean change in cMt; proportion of patients with an increase in cMt of more than 50 μm; and the proportion of patients with new hemorrhages at week 24 and 48. the number of injections received at 24 and 48 weeks and their frequency over the study period were determined. any side effects and adverse events were also recorded.
Patient records were further reviewed at 2 years to determine how many participants had continued with aflibercept injections after study completion.
statistical analysis
statistical analyses were performed in the r statistical environment (r development core team, 2014; r Foundation for statistical computing, Vienna, austria). as the study is small, statistics describing patient characteristics and study outcomes in the whole dataset and stratified according to the anatomical location of the macular exudate [intraretinal (irF), srF, or causing PEd] are presented using medians, with interquartile range (iQr). However, means ± standard deviation (sd) are also presented for information. differences in continuous variables over the study period were assessed using paired student t tests and Mann-Whitney Wilcoxon tests where appropriate. P values less than 0.05 were considered statistically significant. persistent cnV as defined and baseline vision of at least 6/60 were recruited to the study. Eighteen participants completed 1 year of follow-up. one participant was treated in both eyes. a summary of participant characteristics is presented in table 1. one patient died after 4 months from unrelated causes and the data from this individual are not included in the analysis. thirteen of the 18 participants who completed the study were female and slightly older than the males (mean age, 77 vs 73 years; P = 0.1). Before switching to aflibercept, the median duration of treatment with ranibizumab was 73 weeks (iQr: 31, 154) and the median number of injections was 13 (iQr: 7, 25) . the median follow-up period after switching was 54.6 weeks [(iQr: 53.4, 55 .7); range: 51.0, 59.0 weeks].
Visual acuity
Forty-eight weeks after switching to aflibercept, 17 of the 19 treated eyes (90%) had maintained their vision (lost less than 5 letters of visual acuity). the mean and median Etdrs letters read increased by 6 (P = 0.04) and 5 letters (P = 0.06), respectively (table 2) . the baseline visual acuity had a significant negative correlation with the improvement in Va over the study period (r = −0.58, P = 0.009).
oCt measures at Follow-up the differences in cMt and cMtVol over the study period are documented in table 2. as was observed for Va, the changes in cMt and cMtVol over the study period were strongly correlated with baseline values (r = −0.59, P = 0.008). Before switching to aflibercept, the median CMT was 268 μm (IQR: 224, 330). at 24 and 48 weeks after switching, the median cMt was 266 μm (IQR: 217, 287) and 255 μm (IQR: 210, 283), respectively. the change in median cMt between baseline and 24 weeks, after switching to aflibercept, did not quite reach statistical significance (P = 0.056) but the difference was significant at 48 weeks (P = 0.018). compared with baseline, none of the eyes in the study had a greater than 50 μm increase in CMT at 24 or 48 weeks after switching.
the median cMtVol at 24 and 48 weeks after switching to aflibercept was 10.1 mm 3 (iQr: 9.4, 10.35) and 9.8 mm 3 (iQr: 9.15, 10.2), respectively. the reduction in cMtVol at 48 weeks 
Week 8
*approximate Early treatment diabetic retinopathy scores (converted from snellen measures). †significance test using student paired t test for means and Wilcoxon signed rank test for medians; P < 0.05. was of borderline significance (P = 0.088). the median height of PEds did not alter significantly over the follow-up period with 207 μm (IQR: 176, 486) at baseline, 297 μm (IQR: 178, 458) at 24 weeks, and 311 μm (IQR: 169, 422) 48 weeks after switching.
injection Frequency although the period between aflibercept injections was extended to 8 weeks after 3 injections, only 3 eyes (2 with irF and 1 with irF and srF) were being maintained at this frequency at the end of the study. the majority (13/19) had reverted to injections at 4-5 week intervals. Over the follow-up period, the median number of aflibercept injections was 12 (iQr: 11, 13) and the frequency of injection after 3 loading doses [40.5 days (iQr: 31.7, 40.9)] was significantly less than that observed in the previous 12 months of VEgF treatment [33.0 days (iQr: 32.0, 36.5); P = 0.002]. in the subgroup of eyes with irF, there was a statistically significant difference between the median cMt at baseline and
stratified analysis

Fluid Location and Change in Visual Acuity
Visual Acuity and CMT
the association between change in vision and cMt is illustrated in Figure 2 . there were no significant correlations between changes in Va and cMt overall or stratified by the location of the fluid on oct. However, for the 7 participants with PEd, the change in Va over 48 weeks was correlated with the change in height of the PEd (r = −0.754, P = 0.05).
Injection Frequency vs Fluid Location
at baseline the median frequency of injections in the 12 months before switch was similar for all eyes: 33 days (iQr: 32, 40), 34 days (iQr: 33, 37), and 33 days (iQr: 33, 34) for eyes with irF, srF, and PEd, respectively. one year after switching to aflibercept the median frequency of injections was reduced to 46 days [(iQr: 39, 48) ; P = 0.02] in eyes with irF, 41 days [(iQr: 35, 42) ; P = 0.10] in eyes with srF, and 41 days [(iQr: 34, 41) ; P = 0.03] in eyes with PEd.
safety Profile over the study Period during the period of the study, 3 serious adverse events were reported: an 81-year-old female with a history of angina and hypercholesterolemia died at home, a second participant was diagnosed with aggressive bladder cancer and withdrew from the study, and a third participant was hospitalized with a dislocated knee after a fall. none of these events were considered attributable to aflibercept treatment. there were no reports of endophthalmitis or other new safety signals observed during the study follow-up.
Further review of Participants at 2 Years a review of patient records 2 years after commencing aflibercept identified that 14 /18 participant eyes, with current records, were still being treated with aflibercept. Half of those on aflibercept were receiving injections at 8 weekly intervals. Four eyes had been switched back to monthly ranibizumab. central macular thickness measures in both groups remained stable but Va was reduced in 2 patients as a consequence of cataract progression. disCussion in this study we found that aflibercept was effective in preventing loss of visual acuity of 5 or more letters and reducing macular edema in the majority of participants with persistent but stable cnV previously treated with regular monthly ranibizumab. the improvement in vision over 12 months was similar to the 24-week results reported chang et al.
14,15 However, the majority of the improvements in visual acuity and cMt were observed between 24 and 48 weeks and predominantly in eyes with irF. this is in contrast to the observations in naive patients, 12 where a good response may be observed after the first few injections. 14 differences in outcomes may be attributable to the patient selection. ours was a "real life situation" with patients having disease that was stable on monthly ranibizumab treatment. the mean Va of our patients at baseline was similar to that reported by chang, 14 whereas the median cMt at baseline was lower than reported in other prospective studies to date.
14-20 our participants were not experiencing any acute exacerbations or fluctuations that may have provided a more acute response to treatment. such a response was apparent in the study by sarao et al, 16 where a significant decline in Va and increased edema (cMt height) Figure 2 . Change in the visual acuity and CMT between baseline and 48 weeks after switching to aflibercept, according to location of macular edema, in patients with persistent but stable neovascular AMD. Correlation coefficients for associations between changes in VA and anatomical measures: overall, −0.24 (P = 0.33); IRF, −0.59 (P = 0.09); SRF, −0.2 (P = 0.568); PED, −0.14 (P = 0.76).
immediately before switching was apparent. in their 12-month study, they observed a significant and sustained reduction in cMt of 121 µm (sd 126) after 1 injection but the initial improvement in visual acuity [+5.2 letters (sd 8.9)] gradually declined over the study period [+1.8 letters (sd 10.9)] at 12 months.
our study outcomes (changes in vision and cMt) were inversely associated with the respective baseline measures but improvement in vision, the outcome of most interest to the patient, was not always associated with improvement in anatomical parameters, particularly in eyes with srF or PEds (Fig. 2) . Four patients in this study maintained their visual acuity despite increases in cMt. When further investigated, the overall improvement in cMt seemed to be driven by eyes with irF, which had higher mean and median cMt and lower BcVa than patients with srF or PEd. after stratification according to the type of lesion (Fig. 1) there was still a significant decline in cMt in patients with irF only but little change in the cMt of patients with srF or PEd, and no significant change in the height of PEd lesions. this latter finding is in contrast to the findings of Major et al, 21 who observed significant anatomical improvement in up to 80% of eyes with PEd 1 year after switching.
after discounting the loading period, the frequency of injections in these patients was significantly lower than their previous injection regimen with ranibizumab. the mean interval between injections was considerably less than the 2 months indicated in the aflibercept product information and only 3 of 19 eyes were maintained on an 8-week regimen at the end of the 1-year follow-up. the observed difference in the frequency of aflibercept injection is likely to be attributable to the brief extension of the treatment interval after the loading period.
it is possible that despite the extra potency of aflibercept, the initial slow response of the macula to the alternative VEgF may be a consequence of resistance, structural changes, or tachyphylaxis to prior anti-VEgF treatment. our experience suggests that for the majority of patients it may be some time before it would be possible to extend the interval between aflibercept treatments to 2 or 3 months on a regular basis (based on structural and visual outcomes). However, further follow-up of these patients demonstrated that successful extension of the interval between aflibercept injections was feasible in 50% of patients within 2 years of switching treatment.
Potential explanations for this might be the duration of treatment before switching to aflibercept, the proportion of eyes with PEd, or the presence of macular atrophy that was not assessed in this current study. it is also likely that there are genetic determinants that affect an individual's response to anti-VEgF agents. 22, 23 this is 1 of 5 prospective studies [15] [16] [17] [18] [19] investigating visual and anatomical outcomes 1 year after switching patients with persistent macular edema, unresponsive to ranibizumab, to aflibercept. the results of this study concur with the results of a recent meta-analysis, 24 which reported that switching may improve the anatomical outcomes for patients previously treated with and unresponsive to ranibizumab; but although some improvement in visual acuity was observed, the improvements were not statistically significant. the weaknesses of this study include its lack of a control group and its small size, limiting its statistical power and precluding more complex analysis adjusting for baseline vision or cMt. the study's strengths include its prospective nature and investigation of outcomes in a routine real-world clinical setting, and our results are in line with those of a recently published meta-analysis.
24 the meta-analysis also reported that prospective studies such as this one tended to more strongly favor aflibercept than retrospective studies, suggesting the possibility of selection or ascertainment bias. in summary, switching anti-VEgF treatment from ranibizumab to aflibercept is a useful strategy in patients with neovascular aMd not completely responsive to ranibizumab and results in improvements in visual acuity and retinal anatomy, particularly in patients with irF. although the pattern of improvement in patients with resistant disease appears to be slower than in naive patients, the majority experience some visual recovery over a 12-month period. 
